Article

Characteristics and mechanical properties of acrylolpamidronate-treated strontium containing bioactive bone cement

Department of Orthopaedics and Traumatology, The University of Hong Kong, Hong Kong, China.
Journal of Biomedical Materials Research Part B Applied Biomaterials (Impact Factor: 2.33). 11/2007; 83(2):464-71. DOI: 10.1002/jbm.b.30818
Source: PubMed

ABSTRACT The aim of the present study was to determine the influence of surface treatment on the mechanical properties of strontium-containing hydroxyapatite (Sr-HA) bioactive bone cement. Previously we developed an injectable bioactive cement (SrHAC) system composed of Sr-HA powders and bisphenol A diglycidylether dimethacrylate (Bis-GMA). In this study, the Sr-HA powder was subjected to surface treatment using acrylolpamidronate, a bisphosphonate derivative, which has a polymerizable group, to improve the interface between inorganic filler and organic matrix by binding Sr-HA and copolymerizing into the matrix. After surface treatment, the compression strength, bending strength, and stiffness of the resulting composites were defined by using a material testing machine (MTS) according to ISO 5833. The fracture surface of the bone cement specimen was observed with a scanning electron microscope. Invitro cytotoxicity of surface-treated SrHAC was also studied using a tetrazolium-based cell viability assay (MTS/pms) on human osteoblast-like cells, the SaOS-2 cell line. Cells were seeded at a density of 10(4)/mL and allowed to grow in an incubator for 48 h at 37 degrees C. Results indicated that after surface treatment, the compression strength and stiffness significantly improved by 22.68 and 14.51%, respectively. The bending strength and stiffness of the bioactive bone cement also showed 19.06 and 8.91% improvements via three-point bending test. The fracture surface micromorphology after compression and bending revealed that the bonding between the resin to surface-treated filler considerably improved. The cell viability indicated that the treated particles were nontoxic and did not inhibit cell growth. This study demonstrated a new surface chemistry route to enhance the covalent bonds between inorganic fillers and polymer matrix for improving the mechanical properties of bone cement. This method not only improves the overall mechanical performance but also increases osteoblastic activity.

Download full-text

Full-text

Available from: Kenneth M C Cheung, Jun 18, 2015
0 Followers
 · 
179 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Poly (methyl methacrylate) (PMMA) bone cement is widely used in vertebral body augmentation procedures such as vertebroplasty and balloon kyphoplasty. Filling high modulus PMMA increases the modulus of filled verterbra, increasing the risk of fracture in the adjacent vertebra. On the other hand, in porous PMMA bone cements, wear particle generation and deterioration of mechanical performance are the major drawbacks. This study adopts a new approach by utilizing linoleic acid coated strontium substituted hydroxyapatite nanoparticle (Sr-5 HA) and linoleic acid as plasticizer reducing bone cement's modulus with minimal impact on its strength. We determined the compressive strength (UCS) and modulus (Ec), hydrophobicity, injectability, in vitro bioactivity and biocompatibility of this bone cement at different filler and linoleic acid loading. At 20 wt % Sr5-HA incorporation, UCS and Ec were reduced from 63 ± 2 MPa, 2142 ± 129 MPa to 58 ± 2 MPa, 1785 ± 64 MPa, respectively. UCS and Ec were further reduced to 49 ± 2 MPa and 774 ± 70 MPa respectively when 15 v/v of linoleic acid was incorporated. After 7 days of incubation, pre-osteoblast cells (MC3T3-E1) attached on 20 wt % Sr5-HA and 20 wt % Sr5-HA with 15 v/v of linoleic acid group were higher (3.73 ± 0.01 x 10⁴, 2.27 ± 0.02 x 10⁴) than their PMMA counterpart (1.83 ± 0.04 x 10⁴). Incorporation of Sr5-HA with linoleic acid in monomer phase is more effective in reducing the bone cement's stiffness than Sr5-HA alone. Combination of low stiffness and high mechanical strength gives the novel bone cement the potential for use in vertebroplasty cement applications.
    Journal of Biomedical Materials Research Part B Applied Biomaterials 01/2011; 96(1):76-83. DOI:10.1002/jbm.b.31741 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Strontium (Sr) has become more attractive for orthopaedic applications as they can simultaneously stimulate bone formation and prevent bone loss. A Sr-containing bioactive bone cement (Sr-BC) has been designed to fix osteoporotic bone fracture. Sr is a trace element, so the safety of containing Sr is concerned when Sr-BC is implanted in human body. The preclinical assessment of biocompatibility of Sr-BC was conducted according to ISO 10993 standards. MTT assay showed that this bioactive bone cement was non-toxic to mouse fibroblasts, and it met the basic requirement for the orthopaedic implant. The three independent genetic toxicity studies including Ames, chromosome aberration and bone marrow micronucleus assays demonstrated absence of genotoxic components in Sr-BC, which reassured the safety concerns of this novel bone cement. The muscle implantation results in present study were also encouraging. The acute inflammation around the cement was observed at 1week post-implantation; however, no significant difference was observed between control and Sr-BC groups. These responses may be attributed to the presence of the foreign body, but the tissue healed after 12weeks implantation. In summary, the above preclinical results provide additional assurance for the safety of this implant. Sr-BC can be used as a potential alternative to the traditional bone cement.
    12/2013; 33(8):5100-5104. DOI:10.1016/j.msec.2013.07.017
  • [Show abstract] [Hide abstract]
    ABSTRACT: Strontium (Sr) and related compounds have become more attractive in the prevention and treatment of osteoporosis. Previously, we developed a novel bioactive bone cement which is mainly composed of strontium-containing hydroxyapatite (Sr-HA) filler and bisphenol A diglycidylether dimethacrylate (Bis-GMA) resin. This bone cement is superior to conventional polymethylmethacrylate (PMMA) bone cement in bioactivity, biocompatibility, and osseointegration. It also has shown sufficient mechanical strength properties for its use in percutaneous vertebroplasty (PVP) and total hip replacement (THR). In this paper, we review the in vitro, in vivo and clinical evidence for the effectiveness of this bioactive bone cement.
    Frontiers of Medicine in China 05/2008; 2(2):117-126. DOI:10.1007/s11684-008-0022-1